153 related articles for article (PubMed ID: 25343299)
61. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
62. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant.
Sanchez RI; Wang RW; Newton DJ; Bakhtiar R; Lu P; Chiu SH; Evans DC; Huskey SE
Drug Metab Dispos; 2004 Nov; 32(11):1287-92. PubMed ID: 15304427
[TBL] [Abstract][Full Text] [Related]
63. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
64. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
65. Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.
Dahlinger D; Duechting S; Nuecken D; Sydow K; Fuhr U; Frechen S
J Pharmacol Toxicol Methods; 2016; 77():66-75. PubMed ID: 26528794
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450.
Bao SS; Wen J; Zheng X; Zhou Q; Qu GE; Chen MJ; Hu GX
Toxicol Lett; 2018 Nov; 297():1-7. PubMed ID: 30138636
[TBL] [Abstract][Full Text] [Related]
67. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
Li Y; Zhou D; Ferguson SS; Dorff P; Simpson TR; Grimm SW
Xenobiotica; 2010 Nov; 40(11):721-9. PubMed ID: 20937004
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.
Hossain MA; Tran T; Chen T; Mikus G; Greenblatt DJ
J Pharm Pharmacol; 2017 Dec; 69(12):1786-1793. PubMed ID: 28960344
[TBL] [Abstract][Full Text] [Related]
69. The anxiolytic effect of Juniperus virginiana L. essential oil and determination of its active constituents.
Zhang K; Yao L
Physiol Behav; 2018 May; 189():50-58. PubMed ID: 29326032
[TBL] [Abstract][Full Text] [Related]
70. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
71. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
72. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
73. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
74. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
75. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
Zhou D; Andersson TB; Grimm SW
Drug Metab Dispos; 2011 Apr; 39(4):703-10. PubMed ID: 21177984
[TBL] [Abstract][Full Text] [Related]
76. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
77. Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions.
Kazmi F; Sensenhauser C; Greway T
Drug Metab Dispos; 2019 Jan; 47(1):9-14. PubMed ID: 30389730
[TBL] [Abstract][Full Text] [Related]
78. Effects of Herbal Formulas Bojungikgi-tang and Palmijihwang-hwan on Inflammation in RAW 264.7 Cells and the Activities of Drug-Metabolizing Enzymes in Human Hepatic Microsomes.
Jin SE; Ha H; Shin HK
J Med Food; 2018 Nov; 21(11):1173-1187. PubMed ID: 30457473
[TBL] [Abstract][Full Text] [Related]
79. Effect of TSHAC on human cytochrome P450 activity, and transport mediated by P-glycoprotein.
Im Y; Kim YW; Song IS; Joo J; Shin JH; Wu Z; Lee HS; Park KH; Liu KH
J Microbiol Biotechnol; 2012 Dec; 22(12):1659-64. PubMed ID: 23221528
[TBL] [Abstract][Full Text] [Related]
80. Effect of single-walled carbon nanotubes on cytochrome P450 activity in human liver microsomes in vitro.
Asai Y; Sakakibara Y; Inoue R; Inoue R; Nadai M; Katoh M
Biopharm Drug Dispos; 2018 May; 39(5):275-279. PubMed ID: 29719052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
